Every Form 4 that INTL STEM CELL CORP (ISCO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ISCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ISCO filings page.
International Stem Cell CORP (ISCO) reported that director Paul V. Maier disposed of stock options to the issuer on September 16, 2026. The transaction covered 30,000 stock options exercisable at $0.12 per share for common stock and left him with no remaining options of this grant. The options, originally granted on June 11, 2024, had fully vested on June 11, 2025, and were scheduled to expire on June 11, 2034. No Rule 10b5-1 trading plan is reported.
International Stem Cell CORP (ISCO) director Paul V. Maier reported an indirect sale of common stock held through a family trust. On September 11, 2026, the trust sold 32,802 shares of ISCO common stock at $0.32 per share, and the filing reports that no shares remain held indirectly after this transaction. No Rule 10b5-1 trading plan is reported.
International Stem Cell CORP director Don Wright received new stock option awards as compensation. On June 11, 2026, he was granted options to buy 182,584 shares of common stock at an exercise price of $0.178 per share, expiring on June 11, 2036. The shares underlying this option vest on the earlier of June 11, 2027 or the next annual stockholder meeting after the grant date.
He was also granted options for 30,000 shares at an exercise price of $0.170 per share, also expiring on June 11, 2036. The shares underlying this option vest in equal quarterly increments through June 11, 2027, starting on September 11, 2026. These are awards, not open‑market purchases or sales.
International Stem Cell Corp director Paul V. Maier received new stock option awards as compensation. On June 11, 2026 he was granted options to buy 182,584 shares of common stock at an exercise price of $0.178 per share and a separate grant for 30,000 shares at $0.17 per share, all expiring on June 11, 2036. One grant vests in full on the earlier of June 11, 2027 or the next annual stockholder meeting after the grant date, while the other vests in equal quarterly increments through June 11, 2027, starting September 11, 2026. These are awards, not open‑market purchases or sales.